ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
21 hedge funds and large institutions have $15.1M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 1 closing their positions.
3.08% more ownership
Funds ownership: 33.7% → 36.78% (+3.1%)
4% more capital invested
Capital invested by funds: $14.6M → $15.1M (+$524K)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$653K |
| 2 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$84.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$82.9K |
| 4 |
Morgan Stanley
New York
|
+$10.7K |
| 5 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$6.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$314K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$97.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$47.2K |
| 4 |
LWPC
Legacy Wealth Partners (California)
Calabasas,
California
|
-$16.6K |
| 5 |
RFWA
RPg Family Wealth Advisory
Burlington,
Massachusetts
|
-$12K |
CNCR Hedge Fund Activity: Q3 2020 in Review
21 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2020, worth a combined $15.1M — up 3.6% from $14.6M a quarter earlier.
Fund positioning in CNCR was balanced in Q3 2020: 1 fund opened new positions, 1 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $653K. The largest seller was Jane Street, cutting an estimated $314K.
- 21 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2020, unchanged from Q2 2020.
- Funds reported $15.1M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2020, up 3.6% quarter-over-quarter.
- 1 fund opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2020 and 1 closed out, a net change of 0 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2020 was Susquehanna International Group, an estimated $653K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2020 was Jane Street, an estimated $314K sold.
Based on aggregated 13F filings for Q3 2020.